Summary

  • Medsi's digital strategy is economically credible only if SmartMed, online payments, self-check-in, patient records, telemedicine and partner integrations raise utilization of expensive clinical capacity. A booking application that simply moves reception work onto the patient is useful, but it is not enough to justify a healthcare infrastructure valuation.
  • The 2025 numbers show a company with real operating leverage: revenue rose to 61.4 billion roubles, adjusted OIBDA reached 13.2 billion roubles, net profit rose to 5.2 billion roubles, average check rose to about 3,800 roubles and SmartMed appointment records reached 8.8 million. The unresolved issue is how much of that improvement came from price, mix and utilization rather than durable software productivity.
  • Medsi's risk is not demand collapse. It is the opposite problem: a large private provider can collect patient traffic, corporate demand and investor attention, then find that doctors, medical equipment, regulation, data-security obligations and high rouble capital costs still own the economics.
  • The judgment is direct: Medsi is stronger than a conventional clinic roll-up, but its digital platform is not yet proven as a separate moat. It is valuable if it lowers no-shows, cuts administrative labour per visit, improves cross-sell without clinical waste and keeps patients inside Medsi's system. If it mainly supports price inflation and IPO storytelling, the benefit belongs first to the controlling shareholder and bondholders, while patients, insurers, clinicians and franchise partners carry more of the downside.

The incentive begins before the patient enters the building

The patient journey Medsi wants investors to believe in starts on a phone. A patient opens SmartMed, chooses a clinic, confirms a doctor, pays without visiting a cashier, scans a QR code at arrival, receives lab results and recommendations in a medical record, books a follow-up, perhaps speaks to a doctor remotely and later buys medicine through a connected pharmacy route. In that version of the story, the clinic becomes less like a queue managed by reception desks and more like a capacity system. Rooms, diagnostic devices and doctors are scheduled with fewer gaps. The same building sees more reimbursable events.

The same patient is less likely to leak to an unaffiliated lab, pharmacy, mental-health service or competing clinic.

That is the economic incentive. A private healthcare group does not build digital infrastructure because software is fashionable. It does so because offline clinical capacity is expensive and scarce. A magnetic resonance scanner, an operating theatre, a clinical hospital bed, a specialist physician's calendar, a home-care shift and a diagnostic laboratory slot all have high fixed or semi-fixed costs. They create value when the appointment arrives on time, the payer accepts the charge, the physician has the record, the downstream service is scheduled, the insurer does not dispute the episode and the patient returns to the network.

Digital tools matter when they reduce friction in that chain. They do not matter much when they only change the colour of the waiting room.

Medsi's public record gives the strategy enough substance to deserve scrutiny. The group reported 2025 consolidated revenue of 61.4 billion roubles, up 22 percent year on year. It reported adjusted OIBDA of 13.2 billion roubles, against 9.8 billion roubles in 2024, and net profit of 5.2 billion roubles. It also reported that clinics operating under the Medsi brand produced 62.9 billion roubles of revenue, a number that includes franchise clinic revenue not treated as group IFRS revenue. The distinction matters. A brand platform can grow faster than the consolidated company.

Shareholders own the economics of royalty, management fee, procurement scale or patient routing, not necessarily all of the revenue a branded facility rings up.

The operating metrics are equally revealing. At the end of 2025 Medsi said its network included 138 clinics and a home-care service, with 330,000 square metres of assets. Unique patients exceeded 1.8 million. Clinic visits per day rose 9 percent to about 45,000. Services rendered per day rose 9 percent to about 97,000. The average check increased 12 percent to about 3,800 roubles. SmartMed appointment records rose 32 percent to 8.8 million. If those figures describe a system in which digital access is filling available capacity and increasing services per patient episode, Medsi has something more interesting than a private-clinic chain.

If they describe price inflation, brand extension and the transfer of front-desk work from employees to patients, the strategic claim is thinner.

The economics are therefore not solved by saying Medsi is digital. The economic question is whether digital healthcare infrastructure improves clinical throughput enough to pay for integration, security, maintenance, medical compliance, software renewal, partner dependence and the managerial distraction of platform building. In healthcare, a bad software project can increase the number of clicks without increasing the number of treated patients. The technology must make scarce clinical inputs go further. That is the test.

Medsi is a controlled healthcare asset, not a loose network

Medsi is not a small technology company hiding inside healthcare language. It is a large Russian private medical group controlled through the Sistema orbit, with Forbes describing Sistema as controlling 95 percent of the shares and management holding the balance. The company's legal disclosures identify Joint Stock Company "Group of Companies Medsi" as the issuer behind the bond programme. Expert RA's company database lists Medsi's Russian registration identifiers, Moscow region, healthcare industry classification and current credit rating history.

The entity is therefore best read as a healthcare operating company with capital-market access, not as a software vendor or isolated telemedicine product.

The operating perimeter is broad. Public company descriptions refer to a federal private clinic network that provides primary care, emergency and home care, diagnostics, surgery, rehabilitation, laboratory capacity, pharmacies, mental-health services and telemedicine through SmartMed. Later company descriptions in 2026 cite 144 clinics, home care, a laboratory, a pharmacy network and SmartMed, with more than 15,000 employees including more than 6,000 doctors. Earlier 2025 materials put the year-end clinic count at 138, while rating-agency materials used a 145-institution portfolio at the end of July 2025.

Those moving counts are not a scandal. They do show that Medsi's perimeter includes different formats: owned clinics, regional facilities, diagnostic centres, hospitals, franchise projects, pharmacies, home care and partner assets.

That mix makes the business more resilient, but harder to analyse. A clinic chain with 20 premium sites in Moscow has one economic problem: high rent, high salaries and expensive doctors need wealthy patients or insurers. A federal private healthcare group has another: standardization, quality control, regional pricing, procurement, medical licence compliance, brand consistency and information-system integration. A digital platform can help only if it disciplines the complexity.

If regional clinics use different operating routines, if franchise sites do not send clean data, if partner services sit outside a usable patient record, the software layer becomes a marketing roof over fragmented operations.

Medsi's public claims point to an ambition beyond appointment booking. It has a patient application, online consultation routes, an online payment function, self-registration by QR code for holders of voluntary medical insurance policies, access to records and lab results, home doctor calls, mental-health service integration and a role in sleep-algorithm work around a Sber smart ring. It promotes scientific partnerships and competence centres. It runs innovation competitions with Sistema-linked institutions. It also runs procurement procedures and bond-market disclosures like a mature operating company. This is a serious footprint.

The cold point is that serious footprints cost money. A large medical group must employ doctors, nurses, administrators, cleaners, drivers, security, engineers and management. It must lease, own or maintain property. It must buy diagnostic equipment, instruments, consumables, pharmaceuticals, software licences, cloud or server capacity, cyber-security tools, insurance, legal services and medical waste handling. It must comply with medical licensing, personal-data and telemedicine rules.

It has to keep patients from deciding that the state system is good enough, a cheaper private clinic is close enough or a specialist's personal reputation matters more than the Medsi brand.

Medsi's advantage is that it has the scale to attack these costs. Its disadvantage is that scale makes each failure more expensive.

Growth is real, but not all growth creates value

Medsi's recent financial line is impressive. Revenue increased from 41.7 billion roubles in 2023 to 50.3 billion roubles in 2024 and then to 61.4 billion roubles in 2025. Adjusted OIBDA rose from 7.8 billion roubles in 2023 to 9.8 billion roubles in 2024 and then 13.2 billion roubles in 2025. Net profit was 2.1 billion roubles in 2024 and 5.2 billion roubles in 2025. Net debt to adjusted OIBDA was reported at only 0.2 times at the end of 2025, after 0.6 times at the end of 2024. The group is not presenting as a distressed roll-up.

That is the surface. The value question is more specific: how much of the revenue growth came from better economics rather than higher nominal prices? In 2025 Medsi's average check rose 12 percent to about 3,800 roubles. Clinic visits per day and services per day rose 9 percent. Unique patients rose 5 percent. The combination suggests a mixture of price, mix and utilization. That is not a criticism; private healthcare is allowed to raise prices. But an economics editor should separate the sources of growth. A company that raises prices in an inflationary healthcare market can grow revenue without becoming more productive.

A company that raises utilization of fixed assets can create more durable value. A company that shifts patients into higher-margin service bundles can create value if clinical need supports the bundle, but can destroy trust if the patient feels over-treated.

Russia's private healthcare market context makes the distinction important. Industry materials in late 2025 described strong nominal growth in paid and commercial medical services, but repeatedly pointed to medical inflation as a major driver. Some market estimates put paid medical services in 2025 around 1.78 trillion roubles after adjustments, while other commercial-market estimates included broader flows and reached higher totals. Analysts also noted that direct household payments dominate much of the paid-care market, and that the cost of services increased materially. In such a market, every major clinic can report higher revenue.

The better company is the one that can keep margin after wage inflation, imported equipment cost pressure, financing cost and demand sensitivity.

Medsi's margin moved in the right direction. Adjusted OIBDA of 13.2 billion roubles on 61.4 billion roubles of revenue implies an adjusted OIBDA margin a little above 21 percent. That is a strong number for a broad, asset-heavy healthcare provider, but it is not untouchable. MD Medical Group, a different listed Russian private healthcare provider with a more specialized business mix around maternity, fertility, hospital and outpatient services, reported 2025 revenue of 43.455 billion roubles and EBITDA of 13.289 billion roubles, with a 30.6 percent EBITDA margin.

The comparison is not perfect: service mix, accounting, geography and patient economics differ. It still shows that private healthcare profitability depends heavily on segment, asset use and payer mix. Medsi's breadth gives it cross-sell and resilience; it also lowers the odds that every rouble of revenue carries specialty-clinic margin.

This is where digital infrastructure has to earn its place. If SmartMed reduces no-shows, smooths doctor schedules, increases online prepayment, cuts time at reception and turns one visit into clinically appropriate follow-up diagnostics, it supports margin. If it only produces appointment volume while physicians remain the bottleneck, it may add call-centre, cyber-security and product-maintenance cost without solving the main constraint. Medsi's 8.8 million SmartMed appointment records are therefore a useful sign, not a conclusion.

The unit economy of a digital appointment

The easiest way to misread Medsi is to treat each appointment as a digital transaction. It is not. The software may initiate the transaction, but the margin is made or lost in a chain of physical events.

Consider a routine paid specialist consultation. The patient discovers availability, books, pays or confirms insurance eligibility, arrives, registers, sees the physician, possibly receives a prescription, lab order, imaging referral or follow-up. The clinic's gross revenue is the consultation price and any attached service revenue. The direct costs include the doctor's time, medical assistant or nurse support, consumables, administrative handling, facility overhead, payment processing, billing work and allocation of platform costs.

The contribution margin depends on three variables: how full the doctor's calendar is, how much time the episode consumes and whether the episode generates additional medically justified services within Medsi's own network.

Digital tools can affect all three. Online booking can sell unused time slots. Patient reminders can lower no-shows. Prepayment can improve cash conversion and reduce cashier queues. Electronic medical records can reduce duplicate anamnesis and make follow-up more efficient. Test-result visibility can move patients to repeat consultation without a new front-desk transaction. QR self-check-in for insurance patients can cut the administrative seconds needed per arrival. Telemedicine can handle follow-up questions that do not justify a room. Home-care requests can use central scheduling to increase route density.

A good system increases treated episodes per doctor-day and per square metre while protecting clinical quality.

But the same tools can disappoint. Online booking can pull forward demand without increasing doctor supply. Digital records can create more documentation time rather than less. Prepayment can reduce queue time but irritate patients if refunds, insurance approvals or service changes are clumsy. Telemedicine can be constrained by regulation and by the limits of remote diagnosis. A recommendation engine can increase services per patient, but the economic quality of that growth depends on appropriateness and trust. In private healthcare, over-commercializing the care path is a margin strategy that eventually becomes a brand risk.

Medsi's reported numbers allow a rough view. In 2025 it reported about 45,000 clinic visits per day and 97,000 services per day. That is a little over two services per visit. The average check of 3,800 roubles does not translate neatly into revenue per visit because service definitions and revenue recognition differ, but the data suggest a business where bundling and follow-on services matter. The platform's value is therefore not only getting a patient through the door.

It is increasing the chance that the patient remains inside Medsi's care pathway when diagnostics, pharmacy, home care, mental-health consultation or prevention programme becomes relevant.

This is also why patient ownership matters more than isolated software features. The company that controls the booking moment can shape the next step. It can show the patient the next available Medsi slot rather than losing the follow-up to a competitor. It can make test results visible and nudge a clinically required consultation. It can let relatives manage family bookings. It can connect loyalty bonuses to payment behaviour. These are not revolutionary ideas. They are basic consumer-platform tools applied to a regulated clinical context. Their economic value is real because healthcare is high friction.

The limitation is equally basic. A physician's professional time is not a cloud server. Utilization that exceeds clinical capacity causes delay, rushed consultations and patient dissatisfaction. Digital throughput is useful only until it collides with labour scarcity.

Labour is the bottleneck that software cannot wish away

Private healthcare margins are built on people with scarce credentials. Medsi can centralize procurement, standardize administration and automate pieces of the patient journey, but it still needs doctors and nurses in the room. Public descriptions put Medsi's workforce above 15,000 employees, including more than 6,000 doctors in later 2026 company materials. That workforce is an asset and a cost base.

Russia's healthcare labour market is not forgiving. Public and industry reports repeatedly point to shortages of doctors and mid-level medical workers. State providers compete for the same specialists, sometimes with public-sector wage programmes and institutional prestige. Private clinics compete by schedule, pay, facilities and patient mix. The more Medsi expands regionally, the more it must solve local staffing rather than simply move a Moscow brand into a new building.

That labour reality determines how digital investments show up in the accounts. The most attractive version is labour substitution: fewer administrative workers per visit, less time wasted on registration, fewer repeated phone calls, better routing, more doctor time spent on clinical work. The second-best version is labour productivity: doctors see more appropriate patients in a day because records, test results and scheduling are cleaner. The least valuable version is labour complication: more systems to log into, more alerts, more patient messages, more legal documentation and more support requests.

The patient-facing application alone does not prove which version Medsi has. Its growth in SmartMed appointments is encouraging, but not decisive. The better evidence would be same-clinic visits per doctor-hour, no-show rates before and after digital adoption, administrative headcount per thousand visits, online payment share, insurance authorization cycle time, doctor schedule fill rate, app-originated repeat visits and complaints per visit. Those facts are not public in the company's releases. Without them, the platform should be treated as a credible operating tool rather than a proven standalone moat.

There is also a cultural issue. Healthcare staff will tolerate software that removes repetitive work. They will resist software that turns doctors into data-entry clerks. The difference matters for retention. If a private clinic chain spends heavily to recruit specialist doctors, then burdens them with poor workflow, the cost returns as wage pressure or turnover. Medsi's economic problem is not just acquiring technology. It is forcing the technology to respect clinical work.

Capital is cheap only in the press release

Medsi's debt metrics look comfortable. Rating agencies describe low leverage, strong liquidity and solid margins. Expert RA raised the company's public rating record to ruAA on July 23, 2026, after ruAA- ratings in earlier years, and its database shows bond-rating histories for multiple Medsi issues. Earlier Expert RA releases identified three bond series of 3 billion roubles each, with long legal maturities and nearer offer dates.

ACRA's 2025 release kept Medsi at AA-(RU) with a positive outlook and linked that to strong market position, low cyclical demand, diversified services, low leverage, high profitability and strong liquidity.

Those are favourable signals. They do not make expansion free. The Bank of Russia key rate was 14.25 percent on July 23, 2026, after a period when the rate had been much higher. Rouble capital remains expensive by the standards of ordinary clinic payback. A new clinic, diagnostic centre, hospital expansion, software implementation or pharmacy rollout has to compete with a high nominal hurdle rate. The return has to be visible in utilization, pricing, patient retention or strategic positioning.

This is where corporate strategy and capital allocation meet. A clinic opening can be justified by demand density, payer mix and shortage of private capacity. A digital product can be justified by productivity. A franchise can be justified by lower capital intensity and royalty economics. A corporate-client clinic can be justified by anchor demand and partner-funded infrastructure. But each has a different risk transfer. In a partner-funded clinic, the corporate client may supply patient flow or capital, while Medsi supplies operations and brand.

In a franchise, the franchisee may carry local capital and operating risk while Medsi monetizes brand, standards and perhaps procurement. In a fully owned clinic, Medsi carries the full capex and utilization risk.

The Lukoil examples show why this matters. Public reports around Volgograd and Usinsk describe Medsi operating medical centres tied to Lukoil industrial populations, with Vademecum reporting that Lukoil funded construction and equipment for the Volgograd clinic and that Medsi took the entity on long-term lease. That is a different economic model from opening a clinic for uncertain retail footfall. Anchor demand lowers marketing risk and can make utilization more predictable. It also increases dependence on the corporate relationship. If the partner changes priorities, renegotiates terms or internalizes care, the clinic's economics move.

The franchise line is another form of capital-light growth. Medsi's own 2025 releases distinguish group revenue from revenue of clinics operating under the Medsi brand, because franchise-clinic revenue is not group IFRS revenue. Investors should like capital-light brand revenue only if quality control is strict and royalty economics are durable. The downside is that reputational risk can remain with Medsi even when the local balance-sheet risk sits elsewhere.

Digital infrastructure sits across all these models. It can bind franchisees to the system, route patients, enforce standards and give Medsi data. It can also create lock-in for partners who depend on Medsi's booking, record and billing flows. That lock-in is valuable. It is also operationally fragile if integration fails.

Who pays, who benefits and who carries the downside

The economic burden of Medsi's strategy does not fall on one party. Patients pay through direct charges, higher average checks, subscriptions, loyalty mechanics or insurance premiums passed through by employers. Corporate employers pay through voluntary medical insurance and direct medical-service contracts. Insurers pay through claim reimbursements and then defend their own margins through tariff negotiation, authorization limits and network steering. Franchisees and regional partners pay through capital commitments and royalty or operating agreements. Vendors benefit from equipment, software and service contracts.

Sistema benefits if Medsi's growth, ratings and IPO optionality increase the value of its portfolio.

Doctors and staff carry another form of downside: a scaled operating model can standardize work, increase appointment density and expose clinicians to patient messages outside traditional clinic boundaries. Patients carry data risk because a unified medical record, payment history, telemedicine log and app account are sensitive assets. Regulators carry political risk if private healthcare becomes a substitute for weak public access rather than a complement. The state can tolerate private capacity, but it will not ignore a system that appears to extract too much from patients during medical inflation.

The company benefits when it can present digitalization as better service and better efficiency. But the exact distribution of benefits depends on payer mix, which Medsi does not disclose in sufficient detail publicly. Corporate voluntary insurance can bring predictable volume but pressure tariffs. Direct retail patients can carry higher realized price but are more sensitive to affordability and service quality. High-end procedures can lift average check but require expensive doctors and equipment. Home care can be attractive if routes are dense, and costly if travel time overwhelms clinical time.

Mental-health and preventive programmes can deepen lifetime value, but they rely heavily on trust.

That means the central risk-transfer mechanism is pricing power. Medsi's average check rose 12 percent in 2025. Forbes and industry reporting describe broader price increases across private medicine and corporate voluntary insurance. If the price increase is covering wage inflation, imported equipment cost, rent, financing cost and better service, it is normal. If price is covering inefficient expansion, weak software ROI or acquisition integration problems, value is being transferred from patients and employers to the operating platform without a corresponding productivity gain.

The company is currently strong enough to win some of this transfer. Its ratings, brand leadership and patient volume support bargaining power. But private healthcare pricing power is not absolute. Russia has a large public healthcare system, fragmented private competitors, specialist-led patient choice and price-sensitive households. Patients may dislike state waiting times, but they do not have infinite cash.

Competition is fragmented, but alternatives are real

Medsi's public narrative often emphasizes leadership. Forbes profiles place it at the top of Russian private medical company rankings. Medsi itself says it has led the Vademecum private multidisciplinary clinic ranking for years. Rating agencies note its strong market position. Those facts matter because a fragmented market rewards trust, brand and network breadth.

But leadership in a fragmented market is not the same as monopoly. Expert RA explicitly noted the market's high fragmentation when discussing barriers to entry. A patient can choose a state clinic, a local private clinic, a specialist's preferred facility, a diagnostic lab, a premium Moscow competitor, a telemedicine service, a corporate insurance network or, for some procedures, a medical-travel route. A corporate client can tender medical services. An insurer can steer networks. A doctor can move.

Medsi's realistic alternatives are not binary. It could spend less on platform features and more on doctor recruitment. It could focus on high-return Moscow assets rather than regional breadth. It could use franchise expansion to protect capital. It could deepen corporate on-site clinics where anchor demand is visible. It could buy local clinics to acquire doctors and patient flow. It could emphasize high-margin specialties rather than broad outpatient coverage. It could let partners own more digital point solutions and keep Medsi as a clinical operator. Each alternative has costs.

The broad integrated strategy is attractive if Medsi can capture more of the patient's healthcare wallet while keeping utilization high. The risk is managerial sprawl. Pharmacy, home care, mental health, prevention, sleep technology, telemedicine, corporate clinics, franchise expansion, international projects and hospital medicine do not all have the same economics. They can reinforce each other through the patient record and brand. They can also become a portfolio of adjacencies that look coherent only in a presentation.

MD Medical Group is the most useful comparison because it shows a narrower private healthcare model can produce very high margins. MD Medical's 2025 EBITDA margin was above 30 percent and its reported capex was 4.266 billion roubles. Medsi's breadth gives it a larger revenue base and more everyday patient touchpoints, but the narrower model reminds investors that healthcare capital should not be applauded simply for being healthcare capital. The best specialty assets may generate more cash with fewer moving parts.

Medsi's counterargument is scale. If it has the patient funnel, corporate relationships and digital record, it can capture services that a specialty provider cannot. That is plausible. The burden of proof is high.

Regulation turns software into both moat and liability

Healthcare software is not ordinary consumer software. Medsi's app handles medical information, appointment behaviour, payment functions, telemedicine routes and potentially family accounts. Russian personal-data law protects personal data and treats health information as sensitive. Russia's health law recognizes telemedicine technologies and later amendments and health ministry procedures define how remote consultations and monitoring can be organized. Medical activity is licensed. These rules do not make digital healthcare impossible. They make it costly.

Compliance can become a moat for a large incumbent. A small clinic can buy a booking widget. It is harder for a small clinic to maintain secure patient records, telemedicine compliance, payment workflows, consent capture, integration with labs, family booking, insurance check-in and audit trails across regions. Medsi has scale to spread those costs. It also has more to lose if the system fails. A data breach or clinical-process failure at a national brand has higher reputational cost than a problem at an isolated clinic.

Data sovereignty and locality are not abstract policy ideas in this business. Patient records, test results, online consultations, payment histories and family-account links are among the most sensitive categories of consumer data. The software stack must be maintained, monitored, renewed and secured. That means vendor dependence matters. Medsi's public materials do not provide enough detail to identify the full architecture behind SmartMed, its hosting model, security vendors, integration partners, electronic medical record vendors or internal development split. That missing information is not a reason to assume weakness.

It is a reason to avoid giving the platform a software-company valuation without evidence.

The same is true for partner integrations. The announced mental-health partnership with Yasno, and Medsi's participation in sleep-algorithm work around the Sber smart ring, show that the company wants its medical brand inside adjacent digital health services. The economics can be attractive: Medsi contributes clinical credibility, partners bring user interfaces or devices, and the combined service may send patients back into Medsi. The risk is clinical accountability and vendor lock-in. If advice, triage or wellness recommendations move across platforms, patients may not care which legal entity created the bad experience.

They will see the Medsi name.

Security automation is therefore part of the economics. A scaled healthcare platform must automate access control, anomaly detection, audit logging, incident response and permission management. Those systems do not create revenue in a visible way. They prevent loss. Boards often underinvest in prevention until a breach or outage clarifies the price. Medsi's ratings imply comfort with governance and liquidity; they do not remove the operational risk.

Unofficial signals support interest, not proof

Market chatter around Medsi is active because the company sits inside a larger Sistema capital-market story. Interfax, Forbes, Vedomosti, BCS, T-Bank investor posts and Smart-Lab discussions have all treated Medsi as a possible IPO or pre-IPO candidate. The strategic reading is straightforward. Sistema has portfolio assets, parent-level debt concerns and a market incentive to crystallize value in subsidiaries. Medsi's revenue growth, ratings and low leverage make it a natural candidate for external capital.

That market signal cuts both ways. An IPO could give Medsi its own capital, currency for acquisitions and public discipline. It could also be primarily a value-realization event for Sistema. If pre-IPO investors come in before the public market, the valuation they accept will reveal how much of Medsi's digital and network story the market believes. A high valuation would not prove the strategy, but it would show demand for a scarce listed Russian private-healthcare asset.

A weak valuation or delay would say something about capital costs, parent-company risk, Russian equity-market depth and investor doubts about private healthcare growth after inflation.

Patient and app signals are more mixed and should not be overstated. Public app-store listings describe SmartMed as a patient portal with appointment booking, test results, diagnostics, telemedicine, payment and pharmacy functions. Local clinic pages on review platforms such as ProDoctorov, 2GIS and Yandex show that patients judge the business through mundane issues: doctor availability, wait time, price clarity, reception quality, location and the actual consultation. Those are not audited datasets and should not be treated as representative survey evidence. They do, however, confirm the economic reality.

Digital healthcare wins or loses at the point where a patient needs a convenient appointment, a competent physician and a clear bill.

Investor forums tend to focus on Medsi through Sistema, bonds and IPO timing. That is useful as sentiment, not fact. Retail investors naturally care whether Medsi can unlock value for Sistema shares or support bond confidence. Patients care whether they can get care without friction. Those interests overlap only if Medsi's operating efficiency improves. Otherwise one group is monetizing a story the other group funds through price.

The judgment

Medsi is a materially better business than a simple roll-up of private clinics. The company has national scale, a recognizable brand, low reported leverage, strong ratings, a broad service perimeter, corporate-client examples, digital patient access and enough patient volume to make software productivity meaningful. Its 2025 performance shows real operating leverage. The combination of 22 percent revenue growth, 35 percent adjusted OIBDA growth, higher net profit, higher average check, higher visits per day and a large increase in SmartMed appointment records is not cosmetic.

But the digital thesis is not proven at the level investors should require. The public facts show usage, not productivity. They show growth, not the source of value creation. They show a platform interface, not doctor-hour economics. Medsi may have the data internally; it has not put enough of it into the public record to let outsiders separate true throughput gains from price inflation, mix shift and scale effects.

The best current interpretation is that Medsi's digital infrastructure is an operating amplifier, not yet a standalone moat. It amplifies brand reach, payment conversion, appointment convenience, patient retention and cross-sell. It probably reduces some administrative friction. It likely strengthens partner and franchise control. These are valuable.

But a moat would require evidence that competitors cannot replicate the patient journey, that Medsi's same-clinic capacity improves faster than peers, that patient acquisition cost falls, that administrative cost per visit declines and that digital-origin patients have higher lifetime value without excessive clinical utilization.

The downside is also clear. In a high-rate, inflationary healthcare market, a large private provider can look successful because prices rise and patients are frustrated with alternatives. That is revenue growth. It is not automatically value creation. If wage inflation, equipment costs, data-security spending, software maintenance and regional expansion absorb the gains, the shareholders get a large company but not a superior one. If digital systems shift effort onto patients and clinicians without reducing total cost, the operating story weakens.

If corporate partners and franchisees carry more capital risk while Medsi keeps brand upside, the strategy may be clever for Medsi but less attractive for counterparties.

The facts that would change the judgment are specific. First, disclosure of same-clinic revenue growth split by price, volume and mix. Second, evidence that SmartMed users have materially lower no-show rates, higher appropriate repeat visits and lower administrative cost per visit. Third, cohort economics for new clinics, franchise sites and corporate-client clinics. Fourth, payer-mix disclosure showing whether Medsi depends on a narrow set of insurers, employers or regions. Fifth, capex by owned clinics, equipment, software, cyber security and acquisitions. Sixth, patient retention and complaint trends.

Seventh, public evidence of robust security operations and vendor independence. Eighth, IPO documents with segment margins and cash conversion.

Until then, Medsi deserves credit for building the only kind of digital healthcare platform that matters: one attached to real doctors, rooms, equipment and patients. It should not get full credit for turning that platform into defensible economics. The company has the ingredients. The question is whether the software makes the clinic network more productive, or merely makes a capital-intensive healthcare chain easier to sell.

Sources